PBAC's latest decision on Panitumumab: Recommended (2015). Considered for First-line treatment of RAS wild-type metastatic colorectal cancer in combination with oxaliplatin-based chemotherapy.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
5
first 2008
Submissions
5
2008 → 2015
Eligible population
Adults with RAS wild-type metastatic colorectal cancer, WHO performance status 2 or less, previously untreated, receiving first-line oxaliplatin-based chemotherapy
Therapy area
Oncology
Line of therapy
First-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Key trials
CALGB/SWOG 80405
Comparator
cetuximab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated
ICER (historical)
$94k/QALY across 2 submissions (2008–2014) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Risk sharing
Risk-sharing arrangement in place — Panitumumab to join the same risk share arrangement as cetuximab and bevacizumab in the first-line setting
Submission history
Nov 2008: Not recommended · Authority Required — ICER $75k/QALY
Mar 2013: Noted · Authority Required
Nov 2013: Recommended with restriction · Authority Required